RayKnowChina Research Map
Shortlist0

ShenzhenSun Yat-sen University

Seventh Affiliated Hospital of Sun Yat-sen University

中山大学附属第七医院

Listed for 13 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Seventh Affiliated Hospital of Sun Yat-sen University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Stomach cancer胃癌52 papers led
  2. Hepatoblastoma肝母细胞瘤1 paper led
  3. Osteosarcoma骨肉瘤2 papers led
  4. Gastrointestinal stromal tumour胃肠道间质瘤7 papers led
  5. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病2 papers led
  6. Beta thalassaemiaβ 地中海贫血1 paper led
  7. Haemophilia A血友病 A1 paper led
  8. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎1 paper led
  9. Idiopathic pulmonary fibrosis特发性肺纤维化2 papers led
  10. Pompe disease庞贝病1 paper led
  11. Duchenne muscular dystrophy杜氏肌营养不良1 paper led
  12. IgA nephropathyIgA 肾病1 paper led
  13. Hirschsprung disease先天性巨结肠1 paper led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Retinoblastoma, Chordoma, Neuroblastoma, Ewing sarcoma, Multiple myeloma, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Stomach cancer

胃癌

Led 52 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.5%.

Papers led
52
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 7720212022: 111120222023: 101020232024: 9920242025: 15152025

7 hospitals in Shenzhen for stomach cancer218 hospitals in China for stomach cancer

No open trial on stomach cancer lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseImaging & AISurgery
Departments in papersGastroenterology / hepatologyRheumatology & immunology

Over half of these papers are lab or animal studies.

Papers it led52
  1. NPR1 Promotes Lipid Droplet Lipolysis to Enhance Mitochondrial Oxidative Phosphorylation and Fuel Gastric Cancer Metastasis.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  2. Development and validation of a simple prediction risk score for predicting risk of gastric cancer in outpatient department.2025BMC cancerFree full text
  3. A validation study of three early warning scores in early identification of gastric cancer patients with deteriorating condition after gastrectomy.2025BMC gastroenterologyFree full text
  4. m6A demethylation of NNMT in CAFs promotes gastric cancer progression by enhancing macrophage M2 polarization.2025Cancer letters
  5. CD51 promotes gastric cancer stemness via blocking Numb-mediated Notch1 degradation.2025Cancer letters
  6. CHD4 drives gastric cancer metastasis via MYH9/GSK3β/β-catenin axis and WNT/EMT pathway activation.2025Cancer letters
  7. Exosomal Biglycan promotes gastric cancer progression via M2 polarization and CXCL10-mediated JAK/STAT1 activation.2025Cancer letters
  8. Organoid models of drug resistant gastric adenosquamous carcinoma: Recapitulating tumor features and refining precision treatment.2025Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  9. Prognostic modeling of early-onset nondistal gastric cancer identifies ARSB-PDCD1 ratio as an immune-related survival stratifier.2025Frontiers in immunologyFree full text
  10. SUSD2+ cancer-associated fibroblasts in gastric cancer mediate the effect of immunosuppression and predict overall survival and the effectiveness of neoadjuvant immunotherapy.2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  11. Development and Validation of a New Prediction Criteria for Neoadjuvant Chemotherapy Response in Locally Advanced Gastric Cancer Based on Ferroptosis-Related Biomarkers.2025Journal of gastroenterology and hepatologyFree full text
  12. Orphan Class A GPCRs Signature Predicts Prognosis and Immune Microenvironment in Gastric Cancer: GPR176 Drives Tumor Progression Through Wnt Signaling and Macrophage Polarization.2025Mediators of inflammationFree full text
  13. Protocol for tumor prognostic prediction, molecular stratification, and target discovery using a machine learning-driven approach.2025STAR protocolsFree full text
  14. The molecular subtype based on cell cycle-related gene signature predicts the prognosis and chemotherapy and immunotherapy response in gastric cancer.2025Scientific reportsFree full text
  15. Psoas muscle depletion correlates with poor prognosis and compromised immunity in resectable gastric cancer: A multicenter study.2025Seminars in oncology
  16. Gastric Cancer Actively Remodels Mechanical Microenvironment to Promote Chemotherapy Resistance via MSCs-Mediated Mitochondrial Transfer.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  17. DDR1 Drives Malignant Progression of Gastric Cancer by Suppressing HIF-1α Ubiquitination and Degradation.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  18. Pumilio1 regulates NPM3/NPM1 axis to promote PD-L1-mediated immune escape in gastric cancer.2024Cancer letters
  19. RP11-789C1.1 inhibits gastric cancer cell proliferation and accelerates apoptosis via the ATR/CHK1 signaling pathway.2024Chinese medical journalFree full text
  20. NAT10 Overexpression Promotes Tumorigenesis and Epithelial-Mesenchymal Transition Through AKT Pathway in Gastric Cancer.2024Digestive diseases and sciences
  21. SPI1+CD68+ macrophages as a biomarker for gastric cancer metastasis: a rationale for combined antiangiogenic and immunotherapy strategies.2024Journal for immunotherapy of cancerFree full text
  22. OLFM4 promotes the progression of intestinal metaplasia through activation of the MYH9/GSK3β/β-catenin pathway.2024Molecular cancerFree full text
  23. Exosome circATP8A1 induces macrophage M2 polarization by regulating the miR-1-3p/STAT6 axis to promote gastric cancer progression.2024Molecular cancerFree full text
  24. A nomogram predicting distant metastasis risk for gastric cancer patients with preoperative anemia: a multicenter retrospective study.2024World journal of surgical oncologyFree full text
  25. PUM1 Promotes Tumor Progression by Activating DEPTOR-Meditated Glycolysis in Gastric Cancer.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  26. A new modified incision for single-port distal gastrectomy.2023Asian journal of surgery
  27. Pleckstrin-2 promotes tumour immune escape from NK cells by activating the MT1-MMP-MICA signalling axis in gastric cancer.2023Cancer letters
  28. Genome-wide characterization of extrachromosomal circular DNA in gastric cancer and its potential role in carcinogenesis and cancer progression.2023Cellular and molecular life sciences : CMLSFree full text
  29. Downregulation of CYRI-B promotes migration, invasion and EMT by activating the Rac1-STAT3 pathway in gastric cancer.2023Experimental cell research
  30. The DNA damage repair-related lncRNAs signature predicts the prognosis and immunotherapy response in gastric cancer.2023Frontiers in immunologyFree full text
  31. Construction of a hypoxia-immune-related prognostic panel based on integrated single-cell and bulk RNA sequencing analyses in gastric cancer.2023Frontiers in immunologyFree full text
  32. Targeting NAD metabolism regulates extracellular adenosine levels to improve the cytotoxicity of CD8+ effector T cells in the tumor microenvironment of gastric cancer.2023Journal of cancer research and clinical oncologyFree full text
  33. Identification and validation of a PD-L1-related signature from mass spectrometry in gastric cancer.2023Journal of cancer research and clinical oncologyFree full text
  34. Development of a deep learning-based model to diagnose mixed-type gastric cancer accurately.2023The international journal of biochemistry & cell biology
  35. Knockdown and inhibition of hydroxytryptamine receptor 1D suppress proliferation and migration of gastric cancer cells.2022Biochemical and biophysical research communications
  36. METTL3 promotes oxaliplatin resistance of gastric cancer CD133+ stem cells by promoting PARP1 mRNA stability.2022Cellular and molecular life sciences : CMLSFree full text
  37. Identification of a Two-Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival in Diffuse-Type Gastric Cancer.2022Current oncology (Toronto, Ont.)Free full text
  38. Risk Factors and Prognostic Impact of Postoperative Complications in Patients with Advanced Gastric Cancer Receiving Neoadjuvant Chemotherapy.2022Current oncology (Toronto, Ont.)Free full text
  39. The Prognostic Effect of Multidisciplinary Team Intervention in Patients with Advanced Gastric Cancer.2022Current oncology (Toronto, Ont.)Free full text
  40. Schlafen family is a prognostic biomarker and corresponds with immune infiltration in gastric cancer.2022Frontiers in immunologyFree full text
  41. The cancer-associated fibroblast-related signature predicts prognosis and indicates immune microenvironment infiltration in gastric cancer.2022Frontiers in immunologyFree full text
  42. Peritumoral TIGIT+CD20+ B cell infiltration indicates poor prognosis but favorable adjuvant chemotherapeutic response in gastric cancer.2022International immunopharmacology
  43. GALNT1 Enhances Malignant Phenotype of Gastric Cancer via Modulating CD44 Glycosylation to Activate the Wnt/β-catenin Signaling Pathway.2022International journal of biological sciencesFree full text
  44. Signaling pathways and therapeutic interventions in gastric cancer.2022Signal transduction and targeted therapyFree full text
  45. LINC01094 Predicts Poor Prognosis in Patients With Gastric Cancer and is Correlated With EMT and Macrophage Infiltration.2022Technology in cancer research & treatmentFree full text
  46. High expression of vinculin predicts poor prognosis and distant metastasis and associates with influencing tumor-associated NK cell infiltration and epithelial-mesenchymal transition in gastric cancer.2021AgingFree full text
  47. Body composition and risk of gastric cancer: A population-based prospective cohort study.2021Cancer medicineFree full text
  48. Prognostic impact of anatomical extent of metastatic lymph node on gastric cancer: a propensity score matching study.2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  49. Prognostic Significance of ACP5 in Human Gastric Cancer.2021Digestive diseases (Basel, Switzerland)Free full text
  50. The prognostic impacts of PABPC1 expression on gastric cancer patients.2021Future oncology (London, England)
  51. Ailanthus Altissima-derived Ailanthone enhances Gastric Cancer Cell Apoptosis by Inducing the Repression of Base Excision Repair by Downregulating p23 Expression.2021International journal of biological sciencesFree full text
  52. METTL16 promotes cell proliferation by up-regulating cyclin D1 expression in gastric cancer.2021Journal of cellular and molecular medicineFree full text
All its trials on ClinicalTrials.gov, any status1
  1. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in ChinaStatus unknownNCT05638269Study siteStart 2022-03

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led 1 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

3 hospitals in Shenzhen for hepatoblastoma88 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 2 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

23 hospitals in Shenzhen for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 7 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 1.3%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 1120232024: 1120242025: 222025

4 hospitals in Shenzhen for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 2 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 0.9%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

4 hospitals in Shenzhen for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

No open trial on B-cell acute lymphoblastic leukaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesChildren
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led 1 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

7 hospitals in Shenzhen for beta thalassaemia157 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 1 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

4 hospitals in Shenzhen for haemophilia A160 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology
Papers it led1
  1. Recent Advances in Gene Therapy for Hemophilia.2025Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 1 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

6 hospitals in Shenzhen for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 2 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

9 hospitals in Shenzhen for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Pompe disease

庞贝病

Led 1 of the 30 English-language PubMed papers on Pompe disease with an author in mainland China, 2021–2025: 3.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

1 hospital in Shenzhen for Pompe disease30 hospitals in China for Pompe disease

No open trial on Pompe disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

4 hospitals in Shenzhen for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 1 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

10 hospitals in Shenzhen for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led 1 of the 161 English-language PubMed papers on Hirschsprung disease with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

3 hospitals in Shenzhen for Hirschsprung disease82 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

中山大学附属第七医院

Seventh Affiliated Hospital of Sun Yat-sen University

深圳

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Seventh Affiliated Hospital of Sun Yat-Sen University; Seventh Affiliated Hospital Sun Yat-sen University; Seventh Affiliated Hospital of Sun Yat‑Sen University; The Seventh Affiliated Hospital of Sun Yat-sen University

Suggest a correctionDownload the data